Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194953 | 0.82 | NOS3 (0.39) | HMGCRKDM4EHSD17B10 | |
| SCHEMBL12579013 | 0.78 | HSD17B10 (0.45) | HMGCRKDM4EHSD17B10 | |
| SCHEMBL17194949 | 0.77 | ALDH1A1 (0.48) | HMGCRKDM4EHSD17B10 | |
| SCHEMBL18501678 | 0.73 | — | — | |
| SCHEMBL26860466 | 0.72 | HSD17B10 (0.34) | KDM4EHSD17B10 | |
| SCHEMBL8008745 | 0.72 | NOS2 (0.40) | — | |
| SCHEMBL803483 | 0.72 | KDM4E (0.40) | KDM4EHSD17B10 | |
| SCHEMBL17300734 | 0.71 | HMGCR (0.33) | HMGCR | |
| SCHEMBL8019875 | 0.70 | GABRA1 (0.37) | HMGCRKDM4E | |
| SCHEMBL17194951 | 0.69 | PDE2A (0.48) | KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9862688-B2 | Hydrophobically tagged janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044112-A1 | HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK3, JAK1, JAK2 | HMGCR 4074/4885KDM4E 736/4885HSD17B10 3388/4885 |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | JAK3, JAK1, JAK2 | HMGCR 4074/4885KDM4E 736/4885HSD17B10 3388/4885 |
| US-20170044112-A1 | HYDROPHOBICALLY TAGGED JANUS KINASE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | HMGCR 4187/4885KDM4E 1359/4885HSD17B10 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.